These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16334762)

  • 1. Survival after oxaliplatin therapy of irinotecan-pretreated advanced colorectal cancer patients.
    Melichar B; Kohlová T; Vesely P
    Hepatogastroenterology; 2005; 52(66):1707-14. PubMed ID: 16334762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
    Varol U; Karaca B; Cakar B; Sezgin C; Karabulut B; Uslu R
    Am J Clin Oncol; 2013 Aug; 36(4):388-91. PubMed ID: 22643568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
    Abad A; Massutí B; Gallego J; Yuste AL; Manzano JL; Carrato A; Antón A; Marfa X; Diaz-Rubio E;
    Anticancer Drugs; 2004 Jun; 15(5):469-71. PubMed ID: 15166620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer].
    Ishibashi K; Okada N; Ishiguro T; Okita T; Mitsuhashi T; Miyazaki T; Yokoyama M; Matsuki M; Sano M; Inoue N; Ishida H
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2289-91. PubMed ID: 19106599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.
    Rosati G; Rossi A; Germano D; Reggiardo G; Manzione L
    Anticancer Res; 2003; 23(3C):2981-5. PubMed ID: 12926149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
    Santini D; Vincenzi B; La Cesa A; Caricato M; Schiavon G; Spalletta B; Di Seri M; Coppola R; Rocci L; Tonini G
    Oncology; 2005; 69(1):27-34. PubMed ID: 16088232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
    Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
    Bajetta E; Beretta E; Di Bartolomeo M; Cortinovis D; Ferrario E; Dognini G; Toffolatti L; Buzzoni R
    Oncology; 2004; 66(2):132-7. PubMed ID: 15138365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
    Moehler M; Hoffmann T; Hildner K; Siebler J; Galle PR; Heike M
    Z Gastroenterol; 2002 Dec; 40(12):957-64. PubMed ID: 12564419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
    Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
    Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
    Falcone A; Masi G; Allegrini G; Danesi R; Pfanner E; Brunetti IM; Di Paolo A; Cupini S; Del Tacca M; Conte P
    J Clin Oncol; 2002 Oct; 20(19):4006-14. PubMed ID: 12351598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy.
    Recchia F; Rea S; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Di Blasio A; Massa E; Mantovani G
    Oncol Rep; 2003; 10(1):65-9. PubMed ID: 12469146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
    Bamias A; Papamichael D; Syrigos K; Pavlidis N
    J Chemother; 2003 Jun; 15(3):275-81. PubMed ID: 12868555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.
    Goldberg RM
    Clin Colorectal Cancer; 2002 Aug; 2(2):81. PubMed ID: 12453321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.